Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 5, 2007, Pages 505-515

  Li, D ^a   Lu, W ^a   Zhu, J Y ^b   Gao, J ^b   Lou, Y Q ^a   Zhang, G L ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

CYP3A5; Liver; Polymorphism; Population pharmacokinetics; Tacrolimus; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOCHROME P450 3A5; DILTIAZEM; FLUCONAZOLE; INTERLEUKIN 10; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ANALYTICAL ERROR; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT DRAINAGE; BILIRUBIN BLOOD LEVEL; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DONOR; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEMATOCRIT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL MODEL;

ADULT; AGED; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LIVER; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 34548640104     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00850.x     Document Type: Article

References (22)

1. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical Pharmacokinetics, 43, 623 653.
2. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF (1992) Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metabolism Disposition, 20, 753 761.
3. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK-506. Journal of Biological Chemistry, 268, 6077 6080.
4. Goto M, Masuda S, Kiuchi T et al. (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 14, 471 478.
5. Wang W, Jing J, Zheng S, Wu L, Liang T, Yu S, Yan S (2006) Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transplantation, 12, 775 780.
6. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B (2000) In vivo effects of interleukin-10 on human cytochrome P450 activity. Clinical Pharmacology & Therapeutics, 67, 32 43.
7. Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL (2007) Polymorphisms of tumour necrosis factor-α, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clinica Chimica Acta, 383, 133 139.
8. Thomson AH, Whiting B (1992) Bayesian parameter estimation and population pharmacokinetics. Clinical Pharmacokinetics, 22, 427 467
9. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY (2007) Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. Journal of Clinical Pharmacy and Therapeutics, 32, 89 95.
10. Van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clinical Chemistry, 48, 1668 1671.
11. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJD, Chong SS, Lee CG (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics, 12, 437 450.
12. Ameyaw MM, Regateiro F, Li T et al. (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 11, 217 221.
13. Agarwal P, Oldenburg MC, Czarneski JE, Morse RM, Hameed MR, Cohen S, Fernandes H (2000) Comparison study for identifying promoter allelic polymorphism in interleukin 10 and tumour necrosis factor α genes. Diagnostic Molecular Pathology, 9, 158 164.
14. Jusko WJ, Piekoszewski W, Klintmalm GB et al. (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clinical Pharmacology & Therapeutics, 57, 281 290.
15. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models I. Models for covariate effects. Journal of Pharmacokinetics and Biopharmaceutics, 20, 511 528.
16. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. British Journal of Clinical Pharmacology, 56, 205 213.
17. Scheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503 512.
18. Fukatsu S, Yano I, Igarashi T et al. (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. European Journal of Clinical Pharmacology, 57, 479 484.
19. Jacobson P, Ratanatharathorn V, Uberti J, Brundage RC (2001) Factors affecting the pharmacokinetics of tacrolimus (FK506) in haematopoietic cell transplant (HCT) patients. Bone Marrow Transplantation, 28, 753 758.
20. Hu RH, Lee PH, Tsai MK (2000) Clinical influencing factors for daily dose, trough level and relative clearance of tacrolimus in renal transplant recipients. Transplantation Proceedings, 32, 1689 1692.
21. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clinical Chemistry, 51, 1374 1381.
22. Fukudo M, Yano I, Masuda S et al. (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in paediatric living-donor liver transplant recipients. Clinical Pharmacology & Therapeutics, 80, 331 345.